Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Published byKory Cook Modified over 4 years ago

Similar presentations

Presentation on theme: "Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4."— Presentation transcript:

1 Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. A patient with metastatic melanoma was treated with combined BRAF-targeted therapy plus CTLA4 blockade. A, timeline showing treatment schedule and biopsies; B, CD8+ T-cell infiltrate was determined by IHC (×40 magnification). C and D, immune cells isolated from tumors were analyzed by flow cytometry. C, CD3+ lymphocytes (top); populations of CD4+ and CD8+ lymphocytes pregated on CD3+ cells (middle); percentage of CD4+FoxP3+ Tregs and CD4+FoxP3− non-Tregs, pregated on CD3+CD4+ T cells (bottom). FSC-H, forward scatter height. The ratio of CD8+ T cells to CD4+FoxP3+ Treg cells is shown (C) and plotted versus time (D). Zachary A. Cooper et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Download ppt "Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4."

Similar presentations

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.
Synergistic antitumor effect of anti-CD40/CpG and 14

Synergistic antitumor effect of anti-CD40/CpG and 14
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Dose-escalation patient response.

Dose-escalation patient response.
Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.

Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.
Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.

Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Effect of DMF therapy on T cell subsets
Tregs and APC subsets in TDLNs of patients with cervical cancer.

Tregs and APC subsets in TDLNs of patients with cervical cancer.
Supplemental Digital Content 2 – Figure 1

Supplemental Digital Content 2 – Figure 1
Postoperative changes in blood monocyte subsets.

Postoperative changes in blood monocyte subsets.
Volume 17, Issue 2, Pages (February 2009)

Volume 17, Issue 2, Pages (February 2009)
Volume 19, Issue 7, Pages (July 2011)

Volume 19, Issue 7, Pages (July 2011)
mpJX-594 effects on tumor burden and leukocyte influx.

mpJX-594 effects on tumor burden and leukocyte influx.
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

Similar presentations

Ads by Google